Gedeon Richter launches Nalvee in UK
Hungary’s largest drugmaker Gedeon Richter (RICHT: HB) has announced the UK launch of Nalvee (10mg dydrogesterone), a highly bioavailable oral progestogen tablet for hormone replacement therapy (HRT). Dydrogesterone is a long-established body-similar synthetic progestogen that closely mimics natural progesterone.
The company explained that Nalvee is a branded generic of a dydrogesterone-only product which was initially launched in 1961. However, it was withdrawn from the UK market in 2008 due to commercial reasons associated with the decline in HRT use at that time, although it remains available in other markets. Dydrogesterone has shown a favorable safety and tolerability profile spanning its 60 years of use.5
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze